HEM Pharma Inc. (KOSDAQ:376270)
South Korea · Delayed Price · Currency is KRW 33,900
0.00 (0.00%)
At close: Sep 18, 2026
HEM Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Operating Revenue | 16,142 | 12,979 | 15,067 |
Other Revenue | - | - | -0 |
| 16,142 | 12,979 | 15,067 | |
Revenue Growth | 1.54% | -13.86% | - |
Cost of Revenue | 14,094 | 12,355 | 13,452 |
Gross Profit | 2,048 | 624.02 | 1,616 |
Selling, General & Admin | 13,839 | 11,483 | 5,566 |
Research & Development | 4,414 | 3,840 | 3,212 |
Amortization of Goodwill & Intangibles | 377.52 | 321.92 | 183.63 |
Other Operating Expenses | 93.36 | 167.28 | 107.99 |
Operating Expenses | 19,068 | 16,207 | 9,297 |
Operating Income | -17,020 | -15,583 | -7,682 |
Interest Expense | -1,340 | -649.13 | -261.78 |
Interest & Investment Income | 202.71 | 308.57 | 232.77 |
Currency Exchange Gain (Loss) | 334.07 | -8.03 | 43.26 |
Other Non Operating Income (Expenses) | -4,908 | -7,277 | 31.82 |
EBT Excluding Unusual Items | -22,758 | -23,209 | -7,636 |
Gain (Loss) on Sale of Investments | 17.46 | 30.47 | 24.89 |
Gain (Loss) on Sale of Assets | -790.35 | -7.02 | - |
Asset Writedown | -534.93 | -534.93 | - |
Pretax Income | -23,925 | -23,720 | -7,611 |
Income Tax Expense | -3,183 | 3.62 | 35.34 |
Earnings From Continuing Operations | -20,741 | -23,724 | -7,646 |
Minority Interest in Earnings | -131.37 | -118.36 | - |
Net Income | -20,873 | -23,842 | -7,646 |
Net Income to Common | -20,873 | -23,842 | -7,646 |
Net Income Growth | - | - | - |
Shares Outstanding (Basic) | 7 | 7 | 6 |
Shares Outstanding (Diluted) | 7 | 7 | 6 |
Shares Change | 6.02% | 10.68% | - |
EPS (Basic) | -2925.70 | -3389.26 | -1203.00 |
EPS (Diluted) | -2925.70 | -3389.26 | -1203.00 |
EPS Growth | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Free Cash Flow | -18,656 | -18,100 | -12,367 |
Free Cash Flow Per Share | -2614.97 | -2572.96 | -1945.77 |
Gross Margin | 12.69% | 4.81% | 10.72% |
Operating Margin | -105.44% | -120.06% | -50.98% |
Profit Margin | -129.31% | -183.69% | -50.75% |
Free Cash Flow Margin | -115.57% | -139.45% | -82.08% |
EBITDA | -14,273 | -12,989 | -5,259 |
EBITDA Margin | -88.42% | -100.07% | -34.91% |
D&A For EBITDA | 2,746 | 2,595 | 2,422 |
EBIT | -17,020 | -15,583 | -7,682 |
EBIT Margin | -105.44% | -120.06% | -50.98% |
Advertising Expenses | - | 3,163 | 51.21 |